Vascular Biogenics Ltd (NASDAQ:VBLT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
VBLT has been the topic of a number of other reports. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $11.00 price target on shares of Vascular Biogenics in a research note on Tuesday, February 21st. Chardan Capital set a $20.00 price target on Vascular Biogenics and gave the stock a “buy” rating in a research note on Tuesday, November 29th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Vascular Biogenics in a research note on Thursday, December 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $12.90.
Vascular Biogenics (NASDAQ:VBLT) opened at 5.65 on Friday. The firm’s 50 day moving average price is $5.69 and its 200-day moving average price is $5.14. Vascular Biogenics has a 12-month low of $3.03 and a 12-month high of $7.58. The company’s market capitalization is $151.84 million.
WARNING: “Vascular Biogenics Ltd (VBLT) Lowered to Sell at Zacks Investment Research” was published by Web Breaking News and is owned by of Web Breaking News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at http://www.webbreakingnews.com/2017/03/25/vascular-biogenics-ltd-vblt-lowered-to-sell-at-zacks-investment-research.html.
An institutional investor recently raised its position in Vascular Biogenics stock. Menta Capital LLC increased its position in Vascular Biogenics Ltd (NASDAQ:VBLT) by 46.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 115,735 shares of the biopharmaceutical company’s stock after buying an additional 36,482 shares during the period. Menta Capital LLC owned about 0.43% of Vascular Biogenics worth $561,000 at the end of the most recent quarter. 14.95% of the stock is currently owned by hedge funds and other institutional investors.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.